PET/CT在泌尿生殖系统肿瘤中的局限性与陷阱
本文综述了FDG PET/CT在泌尿生殖系统恶性肿瘤应用中的局限性与常见陷阱。由于这类肿瘤的FDG亲和力差异大、解剖部位特殊及CT与PET序贯成像的技术挑战,图像判读易出现假阳性、假阴性及疗效代谢变化评估错误。目前FDG PET/CT并非早期或低危泌尿生殖系统肿瘤初始诊断或分期的标准,但可用于高危患者远处转移、治疗反应及复发的评估。
要点
- FDG PET/CT并非早期或低危泌尿生殖系统肿瘤初始诊断或分期的标准。
- 高危患者可用FDG PET/CT评估远处转移、治疗反应和疾病复发。
- 认识肿瘤代谢亲和力特征和陷阱对准确判读至关重要。
核心结论
- FDG PET/CT在泌尿生殖系统肿瘤诊断中判读困难且陷阱多,可导致假阳性、假阴性及治疗后代谢变化评估错误。
- 目前FDG PET/CT不是早期或低危泌尿生殖系统肿瘤初始诊断或分期的标准治疗。
- 在高危患者中,FDG PET/CT有助于评估远处转移、治疗反应和疾病复发。
研究设计与样本
- 本文为综述,总结FDG PET/CT在泌尿生殖系统肿瘤中的局限性与判读陷阱。
主要发现
- 泌尿生殖系统肿瘤的FDG亲和力存在差异,且肿瘤部位特殊、CT与PET序贯成像存在技术挑战,使PET/CT判读尤为困难。
- 判读陷阱可导致假阳性和假阴性诊断,以及治疗后代谢变化的错误评估。
临床怎么用
- 在高危泌尿生殖系统肿瘤患者中,可考虑使用FDG PET/CT评估远处转移、治疗反应和疾病复发。
- 判读FDG PET/CT时需了解肿瘤代谢亲和力特征及常见陷阱,以提高诊断准确性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hybrid FDG PET/CT plays a vital role in oncologic imaging and has been widely adopted for the staging and restaging of a variety of malignancies. Its diagnostic value in urogenital malignancies is less well-known, not at least because of the variable FDG avidity of these tumor entities, the sites of these tumors, and technical challenges associated with sequential imaging of CT and PET. PET/CT interpretation thus can be especially challenging and is associated with many pitfalls, which can lead to both false-positive and false-negative diagnoses as well as incorrect assessment of metabolic change following therapy. Currently, FDG PET/CT is not the standard of care for the initial diagnosis or staging of early-stage or low-risk urogenital cancers; however, it can help evaluate distant metastatic disease, response to therapy, and disease recurrence in high-risk patients. Knowledge of imaging features of tumor metabolic avidity and pitfalls is essential for accurate interpretation.
引用
- Vasireddi A, Nguyen NC. PET/CT Limitations and Pitfalls in Urogenital Cancers. Semin Nucl Med. 2021. PMID: 34243903. doi:10.1053/j.semnuclmed.2021.06.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。